🎯 Goal Snapshot: CJC-1295 / Ipamorelin for Performance Research
- Primary Research Goal: Growth hormone pulse amplification and optimisation for muscle development and body composition
- Secondary Goals: Enhanced recovery, improved sleep quality, reduction in body fat percentage
- Compounds Studied: CJC-1295 (GHRH analogue) + Ipamorelin (selective GHRP)
- Evidence Base: Clinical pharmacokinetic studies, body composition research, GH secretion studies
- Audience Level: Intermediate — assumes basic understanding of GH axis physiology
- CJC-1295 is a modified GHRH analogue with an extended half-life (~6–8 days) compared to native GHRH (~7 minutes), achieved through DAC (Drug Affinity Complex) technology or by simply modifying the peptide to resist DPP-IV degradation
- Ipamorelin is a selective growth hormone secretagogue that stimulates GH release with minimal effect on cortisol or prolactin — differentiating it from older GHRPs like GHRP-6 and GHRP-2
- Research demonstrates that combining a GHRH analogue (CJC-1295) with a GHRP (Ipamorelin) produces synergistic GH pulse amplification — a combination known as “dual stimulation”
- Clinical studies show CJC-1295 alone can increase mean 24-hour GH levels by 2–10 fold and IGF-1 levels by 1.5–3 fold in healthy adults
- The combination stack is of interest to bodybuilders and athletes researching muscle hypertrophy, fat oxidation, and recovery acceleration
- Both compounds require appropriate cold-chain storage (2–8°C) and must be handled under sterile conditions for research use
Table of Contents
- Common Performance Challenges That Drive GH Research
- Why CJC-1295 and Ipamorelin? The GH Axis Rationale
- CJC-1295: Mechanism and Pharmacokinetics
- Ipamorelin: Selective GH Release Without Side Effects of Older GHRPs
- The Synergistic Effect: Why the Stack Outperforms Either Alone
- Evidence Review: Clinical Data on GH, IGF-1 and Body Composition
- Options Comparison: CJC-1295 (No DAC) vs CJC-1295 (With DAC)
- Practical Research Considerations
- Summary Comparison Table
- Key Research Numbers
- Frequently Asked Questions
- Related Articles
- Related Products
- Related Research Plans
- Scientific References
- Conclusion
Common Performance Challenges That Drive GH Research
Serious bodybuilders and strength athletes operating at intermediate-to-advanced training levels consistently encounter a set of performance plateaus that basic nutrition and training optimisation cannot fully resolve. Among the most commonly reported are: insufficient overnight recovery leading to reduced training volume capacity the following session; progressive loss of lean mass relative to fat after age 30 despite consistent training; slow wound and connective tissue healing that limits training frequency; and difficulty maintaining body composition during caloric surpluses intended to support muscle growth.
These challenges share a common biological denominator: the gradual decline of endogenous growth hormone secretion that begins around age 25–30 and continues at a rate of approximately 14–15% per decade thereafter. By age 40, most individuals produce roughly half the GH of their peak-youth levels, with corresponding reductions in IGF-1, the primary anabolic mediator of GH’s effects on muscle and bone.
Research into growth hormone secretagogues — compounds that stimulate the body’s own GH production rather than administering exogenous GH directly — has grown substantially over the past two decades as an approach to addressing this physiological decline while preserving the natural pulsatile GH secretion pattern. CJC-1295 and Ipamorelin represent two complementary compounds that target different receptors in the GH regulatory axis, and their combination has become one of the most studied secretagogue stacks in this research domain.
Why CJC-1295 and Ipamorelin? The GH Axis Rationale
The hypothalamic-pituitary axis regulates GH secretion through two primary signalling molecules: Growth Hormone Releasing Hormone (GHRH), which stimulates GH release from the pituitary, and Somatostatin, which inhibits it. Additionally, the GH secretagogue receptor (GHS-R), also called the ghrelin receptor, provides a secondary stimulatory pathway that operates independently of GHRH signalling.
This dual-pathway architecture is the mechanistic rationale for the CJC-1295 / Ipamorelin combination. CJC-1295 is a synthetic analogue of GHRH that activates the GHRH receptor pathway, while Ipamorelin is a synthetic pentapeptide that activates the GHS-R pathway. By stimulating both receptor systems simultaneously, the combination produces a GH pulse that is substantially larger than what either compound achieves alone — a synergistic effect documented in clinical pharmacology research.
The appeal of this approach for performance researchers is multi-layered: it preserves the natural pulsatile secretion of GH (unlike continuous exogenous GH administration, which suppresses this pattern); it does not directly suppress the pituitary’s own regulatory capacity; and by acting on GHRH and ghrelin receptors rather than administering GH directly, it avoids the supraphysiological IGF-1 levels associated with exogenous HGH use.
CJC-1295: Mechanism and Pharmacokinetics
Native GHRH is a 44-amino-acid peptide with an extraordinarily short half-life of approximately 7 minutes in plasma, rapidly degraded by dipeptidyl peptidase IV (DPP-IV) and other serum proteases. CJC-1295 was developed to overcome this pharmacological limitation while preserving the biological activity of GHRH at its receptor.
Two versions of CJC-1295 are widely referenced in research literature. The version commonly called “CJC-1295 with DAC” (or “CJC-1295 DAC”) incorporates a Drug Affinity Complex that enables covalent binding to serum albumin, dramatically extending the half-life to approximately 6–8 days and producing sustained, steady-state elevation of GH and IGF-1 without the natural pulsatile peaks. The version referred to as “CJC-1295 No DAC” (also known as Modified GRF(1-29) or Mod GRF 1-29) lacks this albumin-binding moiety and has a half-life of approximately 30 minutes — long enough to allow research administration on a more frequent basis while preserving GH pulsatility.
Clinical trials by Teichman and colleagues (2006) — published in the Journal of Clinical Endocrinology and Metabolism — demonstrated that CJC-1295 with DAC administered to healthy adults produced mean GH concentration increases of 2-fold to 10-fold and IGF-1 increases of approximately 1.5 to 3-fold, with effects persisting for up to 14 days following a single administration. This study provided foundational pharmacokinetic data for subsequent research into the compound.
Key Insight: Research community opinion on CJC-1295 with DAC vs. No DAC is divided. The DAC version produces sustained GH elevation but blunts the pulsatile nature of GH secretion — a physiological pattern many researchers consider important to preserve. No DAC versions allow pulsatile peaks when dosed around natural GH release windows (particularly pre-sleep and post-exercise).
Why It Matters: Pulsatile GH secretion may be mechanistically important for downstream IGF-1 signalling in muscle tissue. Researchers studying body composition outcomes have begun to prioritise the No DAC version for this reason, representing a meaningful evolution in research design for performance-oriented investigations.
Ipamorelin: Selective GH Release Without Side Effects of Older GHRPs
Ipamorelin (INN name: ipamorelin) is a synthetic pentapeptide growth hormone secretagogue developed by Novo Nordisk in the 1990s. It acts as a selective agonist at the ghrelin receptor (GHS-R1a) in the pituitary gland, triggering GH release through a mechanism entirely independent of GHRH signalling.
What distinguishes Ipamorelin from older growth hormone releasing peptides — particularly GHRP-6 and GHRP-2 — is its selectivity profile. Older GHRPs were found to significantly stimulate cortisol and prolactin release alongside GH, producing side effects including increased appetite (GHRP-6 notably via ghrelin receptor activity in the hypothalamus), water retention, and potential interference with recovery through elevated cortisol. Ipamorelin demonstrates minimal cortisol or prolactin stimulation at research-relevant doses, making it the most selectivity-favourable GHRP studied to date.
Research by Raun and colleagues (1998) published in the European Journal of Endocrinology confirmed Ipamorelin’s potent and selective GH-releasing action in animal models, establishing its pharmacological profile. Subsequent research has validated this selective action in human models, supporting its use in combination studies where minimising off-target hormonal stimulation is a research priority.
The Synergistic Effect: Why the Stack Outperforms Either Alone
The scientific rationale for combining a GHRH receptor agonist (CJC-1295) with a GHS-R agonist (Ipamorelin) is grounded in the known physiology of GH regulation. Both receptor pathways independently converge on pituitary somatotroph cells, and research has demonstrated that simultaneous activation of both pathways produces GH pulses significantly larger than those achieved by either pathway alone — an effect termed “synergistic co-secretion.”
The mechanistic basis is understood at the intracellular level. GHRH receptor activation increases intracellular cAMP, while GHS-R activation increases intracellular calcium via IP3 signalling. These two second messenger pathways converge on the somatotroph secretory machinery in an additive-to-synergistic fashion, releasing substantially more stored GH with each combined pulse than with single-pathway activation.
From a practical research standpoint, this synergy means that the combined stack achieves greater GH secretion at lower individual doses of each compound than would be required if either were used in isolation — a pharmacological efficiency of interest to researchers seeking to study GH axis stimulation with minimal compound burden.
Key Insight: Research into GH secretion timing has identified two primary physiological windows of heightened GH responsiveness: the first 90 minutes of deep sleep (slow-wave sleep) and the 30–60 minutes following high-intensity resistance training. These windows represent periods when the pituitary is naturally primed for GH release.
Why It Matters: Research protocols studying the CJC-1295 / Ipamorelin stack often align administration with these physiological windows to investigate whether GH pulse amplification is greater when timed with natural secretion peaks — a design variable that bodybuilders and performance researchers find particularly relevant to real-world training schedules.
Evidence Review: Clinical Data on GH, IGF-1 and Body Composition
The evidence base for CJC-1295 is anchored by Teichman et al. (2006) — the most rigorous clinical study of the compound — which enrolled 65 healthy adult subjects across dose-ranging cohorts. The study demonstrated dose-dependent increases in mean 24-hour GH concentrations (2 to 10-fold above baseline) and IGF-1 elevations of 1.5 to 3-fold, sustained over the study duration. The compound was well tolerated, with the most commonly reported adverse event being mild flushing — consistent with GH pulse-related vasodilation.
For Ipamorelin, the primary clinical evidence comes from Raun et al. (1998) and subsequent pharmacology studies confirming its GH-selective profile. The selectivity data — showing minimal cortisol and prolactin stimulation compared to GHRP-2 and GHRP-6 at equipotent GH-stimulating doses — has been replicated across multiple independent research groups.
Body composition data specific to the CJC-1295 / Ipamorelin combination is less extensive in published literature than GH secretion data, but several small investigator-initiated studies and mechanistic analyses support the hypothesis that sustained, physiologically elevated IGF-1 promotes lean mass accrual and fat oxidation through well-characterised IGF-1 receptor pathways in muscle and adipose tissue. IGF-1 promotes skeletal muscle protein synthesis through the PI3K-Akt-mTOR pathway and inhibits lipolytic suppression in adipocytes, providing a plausible biological mechanism for the body composition effects studied by researchers.
Options Comparison: CJC-1295 (No DAC) vs CJC-1295 (With DAC)
| Parameter | CJC-1295 No DAC (Mod GRF 1-29) | CJC-1295 With DAC |
|---|---|---|
| Half-life | ~30 minutes | ~6–8 days |
| GH Pattern | Pulsatile (preserves natural rhythm) | Sustained steady-state elevation |
| Administration Frequency | Multiple times weekly (timing with GHRP) | Once or twice weekly |
| IGF-1 Elevation | Episodic, following pulsatile GH | Sustained 1.5–3x baseline |
| Research Use Case | Pulsatility studies, performance-timing research | Long-duration GH elevation studies |
| Combination with Ipamorelin | Timed together for synergistic pulses | Ipamorelin used separately for pulse amplification |
Practical Research Considerations
Research into the CJC-1295 / Ipamorelin stack involves several practical variables that investigators must account for in study design. Storage is a critical consideration: both peptides in lyophilised form should be stored at -20°C before reconstitution and at 2–8°C after reconstitution, with use within 28 days of reconstitution generally recommended based on stability data. Cold-chain integrity during shipping and storage is essential for maintaining peptide structural fidelity and biological activity.
Reconstitution of lyophilised peptides requires bacteriostatic water for injectable research applications. Contamination risk and sterile technique are paramount considerations in any research involving injectable compounds. Researchers must adhere to institutional biosafety protocols and ethical guidelines governing the use of research peptides in human subjects research.
Timing variables are another active area of investigation. Because GH secretion is naturally pulsatile and tied to the sleep-wake cycle, research protocols studying the CJC-1295 / Ipamorelin stack often incorporate pre-sleep or post-training administration windows and measure GH and IGF-1 responses relative to baseline values established during run-in periods. Controlling for diet (particularly carbohydrate intake, which suppresses GH release), sleep quality, and concurrent training load are important confounders in body composition outcome studies.
Summary Comparison Table: CJC-1295 + Ipamorelin Stack
| Research Variable | CJC-1295 Alone | Ipamorelin Alone | Combined Stack |
|---|---|---|---|
| GH Pulse Magnitude | Moderate elevation | Moderate elevation | Synergistic (significantly higher) |
| Cortisol Stimulation | Minimal | Minimal | Minimal |
| Prolactin Stimulation | None | Minimal | Minimal |
| IGF-1 Elevation | 1.5–3x baseline (DAC version) | Episodic with GH pulse | Enhanced sustained elevation |
| Pulsatile GH Preservation | Partially (No DAC version best) | Yes | Yes (with No DAC version) |
| Appetite Effect | None | Minimal | Minimal |
Key Research Numbers
Statistics Section: CJC-1295 / Ipamorelin in Numbers
- 2–10 fold — increase in mean 24-hour GH concentrations demonstrated in Teichman et al. (2006) CJC-1295 clinical trial
- 1.5–3 fold — IGF-1 elevation above baseline in the same CJC-1295 DAC clinical study
- 6–8 days — half-life of CJC-1295 with DAC via albumin-binding technology
- ~7 minutes — half-life of native GHRH (versus CJC-1295’s vastly extended duration)
- ~30 minutes — half-life of CJC-1295 without DAC (Mod GRF 1-29)
- 14–15% per decade — rate of GH secretion decline in adults after peak levels in youth
- 65 subjects — number enrolled in Teichman et al. 2006 dose-ranging clinical study of CJC-1295
- 14 days — duration of IGF-1 elevation observed following a single CJC-1295 DAC dose in the Teichman trial
Frequently Asked Questions
A: CJC-1295 is a modified GHRH analogue that activates the GHRH receptor in the pituitary to stimulate GH release. Ipamorelin is a synthetic GHRP (growth hormone releasing peptide) that activates the separate ghrelin receptor (GHS-R) pathway. They stimulate GH through different but complementary receptor systems, which is why combining them produces synergistic GH release greater than either compound alone.
A: Ipamorelin demonstrates high selectivity for GH release with minimal stimulation of cortisol and prolactin, whereas older GHRPs like GHRP-6 and GHRP-2 significantly elevate these hormones. GHRP-6 also strongly stimulates appetite via ghrelin receptor activity in the hypothalamus. For researchers studying GH effects in isolation without confounding hormonal side effects, Ipamorelin’s selectivity profile makes it the preferred research GHRP.
A: Both compounds stimulate GH and consequently IGF-1 elevation. IGF-1 is a well-established anabolic mediator that activates the PI3K-Akt-mTOR pathway in skeletal muscle, promoting protein synthesis. Whether the GH/IGF-1 elevations produced by these compounds translate to meaningful muscle hypertrophy in human subjects requires controlled clinical research. Current evidence is primarily mechanistic and pharmacokinetic rather than from long-duration body composition randomised controlled trials.
A: The combination is of significant research interest for bodybuilding and performance science applications given its dual mechanism of GH axis stimulation, documented IGF-1 elevation, minimal off-target hormonal effects, and preservation of pulsatile GH patterns. Researchers studying GH secretagogue stacks in athletic populations typically consider this combination the most pharmacologically rational starting point given the available evidence base.
A: Lyophilised (freeze-dried) peptides should be stored at -20°C before reconstitution. After reconstitution with bacteriostatic water, they should be refrigerated at 2–8°C and used within 28 days. Cold-chain integrity during shipping is essential. Vietnam Peptides ships research peptides with appropriate cold-chain packaging to maintain stability.
A: DAC stands for Drug Affinity Complex — a chemical modification that enables CJC-1295 to bind covalently to serum albumin in blood plasma. Since albumin has a half-life of approximately 19 days, this binding dramatically extends CJC-1295’s effective half-life from ~30 minutes (without DAC) to approximately 6–8 days. This produces sustained GH and IGF-1 elevation rather than the episodic pulsatile peaks seen with the No DAC version.
A: CJC-1295 and Ipamorelin are research compounds. Vietnam Peptides supplies them strictly for scientific investigation. Regulatory status varies by jurisdiction — researchers should verify applicable local regulations before procurement or use in any research context.
A: Exogenous HGH (recombinant human growth hormone) directly administers the hormone, bypassing the hypothalamic-pituitary regulatory axis and often producing supraphysiological IGF-1 levels with corresponding side effect risk. The CJC-1295 / Ipamorelin stack stimulates endogenous GH production through natural receptor pathways, preserving regulatory feedback mechanisms and producing more physiological GH and IGF-1 patterns. Researchers interested in GH axis physiology often prefer the secretagogue approach for investigations where preserving regulatory biology is a design priority.
Related Articles
- Vietnam Peptides Knowledge Hub — research guides for peptides across all categories
- Peptide FAQ: Research, Storage and Usage — essential reading for new researchers
- Browse Performance Research Peptides
Related Research Products
Research-grade GH secretagogue stack combining GHRH analogue and selective GHRP for GH axis investigations.
View Product →Research-grade recombinant human growth hormone for comparative GH research studies and performance investigations.
View Product →Related Research Plans
For researchers investigating performance, body composition, and GH axis optimisation, this plan provides compound selection frameworks and research design guidance.
Explore the Total Body Transformation Plan →Scientific References
- Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 91(3):799–805. DOI: 10.1210/jc.2005-1536
- Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 139(5):552–61. DOI: 10.1530/eje.0.1390552
- Smith RG. (2005). Development of growth hormone secretagogues. Endocr Rev. 26(3):346–60. DOI: 10.1210/er.2004-0019
- Veldhuis JD, Bowers CY. (2010). Human GH pulsatility: an ensemble property regulated by age and gender. J Endocrinol Invest. 33(6):387–401. DOI: 10.1007/BF03346615
- Frohman LA, Jansson JO. (1986). Growth hormone-releasing hormone. Endocr Rev. 7(3):223–53. DOI: 10.1210/edrv-7-3-223
- Bowers CY, Reynolds GA, Durham D, et al. (1990). Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 70(4):975–82. DOI: 10.1210/jcem-70-4-975
- Ghigo E, Arvat E, Muccioli G, Camanni F. (1997). Growth hormone-releasing peptides. Eur J Endocrinol. 136(5):445–60. DOI: 10.1530/eje.0.1360445
- Hartman ML, Veldhuis JD, Thorner MO. (1993). Normal control of growth hormone secretion. Horm Res. 40(1–3):37–47. DOI: 10.1159/000183766
Conclusion
CJC-1295 and Ipamorelin represent two of the most pharmacologically rational and research-validated growth hormone secretagogues available for scientific investigation. Their complementary receptor mechanisms — GHRH pathway activation (CJC-1295) and GHS-R pathway activation (Ipamorelin) — produce synergistic GH release that exceeds what either compound achieves independently, while preserving physiological pulsatility and avoiding the cortisol and prolactin stimulation associated with older GHRPs.
For bodybuilders, strength athletes, and performance researchers investigating GH axis optimisation, muscle hypertrophy mechanisms, and body composition research, the CJC-1295 / Ipamorelin stack provides a scientifically grounded research tool with clinical pharmacokinetic data supporting its GH and IGF-1 effects. Body composition outcomes require further large-scale controlled investigation, but the mechanistic case is supported by well-characterised IGF-1 signalling biology.
Vietnam Peptides supplies research-grade CJC-1295 / Ipamorelin 10mg stack for investigators meeting scientific use criteria. Explore the full product range at our Products Page or visit the Knowledge Hub for additional research resources.
Primary Entity: CJC-1295 / Ipamorelin GH Secretagogue Stack
Related Entities: GHRH (Growth Hormone Releasing Hormone), Ghrelin Receptor (GHS-R1a), IGF-1, Somatotrophs, Pituitary Gland, DAC (Drug Affinity Complex), GHRP-6, GHRP-2, HGH, Teichman et al. 2006, Raun et al. 1998, mTOR, PI3K-Akt pathway
Search Intent: Goal-Based / Commercial Investigation — understanding CJC-1295 and Ipamorelin for performance and muscle research
Key Questions Answered: What is CJC-1295? What is Ipamorelin? How do they work together? CJC-1295 vs DAC vs No DAC? Does the stack increase IGF-1? How does Ipamorelin compare to GHRP-6?
Evidence Sources: Teichman et al. 2006 (JCEM), Raun et al. 1998 (Eur J Endocrinol), Smith 2005 (Endocr Rev), Bowers et al. 1990 (JCEM), Veldhuis & Bowers 2010
Relevant User Profiles: Bodybuilders, Athletes, Performance Researchers, Sports Scientists, Biohackers, Men Over 40, Personal Trainers
Knowledge Graph Connections: CJC-1295 → GHRH Analogue → GH Secretion → IGF-1 → Muscle Hypertrophy → Body Composition → Ipamorelin → GHS-R Agonist → Synergistic GH Release → Performance Research